TYK2 Inhibitor Crystalline Forms for Selectivity and Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases targeting TYK2 kinase are limited, and there is a need for more selective and potent inhibitors to address the imbalance in cytokine signaling pathways associated with these diseases.
Innovation Solution
Development of crystalline forms of the compound 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]oxazole-4-carboxamide, which exhibit improved potency and pharmacokinetic properties as TYK2 kinase inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TYK2 inhibitors are used, then some therapeutic effect is achieved, but selectivity and potency are insufficient
Solution Approach 1:
The patent modifies the molecular structure of TYK2 inhibitors by changing chemical parameters - specifically incorporating a thiazinane carbonyl group at the 4-position of the oxazole ring and a carboxamide group at the 5-position. These structural parameter changes result in improved selectivity for TYK2 over other JAK family members and enhanced potency, resolving the technical contradiction between selectivity and potency requirements.
2Reliability
If existing TYK2 inhibitors are used, then some therapeutic effect is achieved, but pharmacokinetic properties need improvement
Solution Approach 1:
The patent alters pharmacokinetic parameters by modifying the molecular structure with specific functional groups (thiazinane carbonyl and carboxamide) that influence absorption, distribution, metabolism, and excretion properties. These structural modifications result in improved pharmacokinetic profiles including enhanced duration of action, while maintaining therapeutic efficacy.
3Reliability
If more potent TYK2 inhibitors are developed, then therapeutic effectiveness improves, but development complexity increases
Solution Approach 1:
The patent segments the molecular structure into distinct functional components: an oxazole core scaffold, a thiazinane carbonyl group at the 4-position providing kinase inhibition activity, and a carboxamide group at the 5-position influencing pharmacokinetics. This segmentation allows independent optimization of each component's contribution to therapeutic effectiveness while managing development complexity through modular design.
Data Source
AI summary
The invention provides crystalline forms of a compound having the formula (1):along with methods of making the crystalline forms and pharmaceutical formulations comprising the crystalline forms.